Ionis Advances Dravet Syndrome Candidate with First Patient Dosed in ASCEND Study
Event summary
- Ionis dosed the first participant in its Phase 1-2 ASCEND study of ION337 for Dravet syndrome on July 13, 2026.
- ION337 is an RNA-targeted medicine designed to increase NaV1.1 protein production in patients with SCN1A gene variants.
- The ASCEND study will evaluate safety and tolerability in children aged 2-12 years, with dosing every six months.
- ION337 uses Ionis' NMA technology for enhanced potency and infrequent dosing potential.
The big picture
Ionis is advancing its neurology pipeline with ION337, a wholly owned asset developed using its proprietary NMA technology. This move aligns with broader industry trends toward RNA-targeted therapies for rare neurological conditions where current treatments are limited to symptomatic management. The company's track record includes successful approvals like SPINRAZA and QALSODY, positioning it as a key player in the neurology space.
What we're watching
- Clinical Progress
- The pace at which ION337 demonstrates safety and efficacy in the ASCEND study will determine its path to potential approval.
- Technological Edge
- Whether Ionis' NMA technology can deliver on its promise of sustained activity and infrequent dosing will be critical for ION337's competitive positioning.
- Market Opportunity
- How ION337 performs in Dravet syndrome could influence Ionis' strategy in other rare neurological diseases within its pipeline.